Neurocrine Biosciences, Inc. (NBIX)
USD 90.49
(-0.25%)
USD 90.49
(-0.25%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.59 Billion USD | 19.41% |
| 2022 | 1.21 Billion USD | 33.48% |
| 2021 | 911.4 Million USD | 28.67% |
| 2020 | 708.3 Million USD | 27.83% |
| 2019 | 554.1 Million USD | 35.33% |
| 2018 | 409.45 Million USD | 40.35% |
| 2017 | 291.73 Million USD | 79.67% |
| 2016 | 162.37 Million USD | 42.47% |
| 2015 | 113.97 Million USD | 76.94% |
| 2014 | 64.41 Million USD | 22.46% |
| 2013 | 52.59 Million USD | 1.75% |
| 2012 | 51.69 Million USD | 19.08% |
| 2011 | 43.4 Million USD | -8.08% |
| 2010 | 47.22 Million USD | -6.75% |
| 2009 | 50.63 Million USD | -44.52% |
| 2008 | 91.27 Million USD | -57.24% |
| 2007 | 213.46 Million USD | 39.93% |
| 2006 | 152.55 Million USD | 2.41% |
| 2005 | 148.96 Million USD | 8.33% |
| 2004 | 137.51 Million USD | -30.5% |
| 2003 | 197.86 Million USD | 62.64% |
| 2002 | 121.66 Million USD | 42.92% |
| 2001 | 85.12 Million USD | 62.49% |
| 2000 | 52.38 Million USD | 35.02% |
| 1999 | 38.8 Million USD | 28.9% |
| 1998 | 30.1 Million USD | 11.9% |
| 1997 | 26.9 Million USD | 55.49% |
| 1996 | 17.3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 397.2 Million USD | 11.45% |
| 2024 Q2 | 426.7 Million USD | 7.43% |
| 2024 Q3 | 429.3 Million USD | 0.84% |
| 2023 Q1 | 382.2 Million USD | 27.02% |
| 2023 Q4 | 356.4 Million USD | 2.89% |
| 2023 FY | 1.45 Billion USD | 19.41% |
| 2023 Q3 | 346.4 Million USD | -5.77% |
| 2023 Q2 | 367.6 Million USD | -3.82% |
| 2022 Q4 | 300.9 Million USD | 2.35% |
| 2022 FY | 1.21 Billion USD | 33.48% |
| 2022 Q2 | 318.7 Million USD | 5.22% |
| 2022 Q3 | 294 Million USD | -7.75% |
| 2022 Q1 | 302.9 Million USD | 24.19% |
| 2021 Q1 | 202.2 Million USD | 16.74% |
| 2021 Q4 | 243.9 Million USD | -1.37% |
| 2021 Q3 | 247.3 Million USD | 13.44% |
| 2021 Q2 | 218 Million USD | 7.81% |
| 2021 FY | 911.4 Million USD | 28.67% |
| 2020 Q2 | 177.4 Million USD | 0.74% |
| 2020 Q4 | 173.2 Million USD | -4.63% |
| 2020 FY | 708.3 Million USD | 27.83% |
| 2020 Q1 | 176.1 Million USD | 12.45% |
| 2020 Q3 | 181.6 Million USD | 2.37% |
| 2019 Q2 | 142.51 Million USD | 13.84% |
| 2019 FY | 554.1 Million USD | 35.33% |
| 2019 Q1 | 125.19 Million USD | 15.82% |
| 2019 Q3 | 129.76 Million USD | -8.94% |
| 2019 Q4 | 156.6 Million USD | 20.68% |
| 2018 FY | 409.45 Million USD | 40.35% |
| 2018 Q3 | 95.88 Million USD | -2.06% |
| 2018 Q4 | 108.08 Million USD | 12.73% |
| 2018 Q1 | 107.58 Million USD | 31.32% |
| 2018 Q2 | 97.9 Million USD | -9.0% |
| 2017 Q2 | 63.54 Million USD | -20.5% |
| 2017 Q4 | 81.92 Million USD | 23.5% |
| 2017 FY | 291.73 Million USD | 79.67% |
| 2017 Q3 | 66.33 Million USD | 4.4% |
| 2017 Q1 | 79.93 Million USD | 72.82% |
| 2016 Q3 | 38.43 Million USD | -8.11% |
| 2016 Q1 | 35.85 Million USD | 16.62% |
| 2016 Q2 | 41.82 Million USD | 16.65% |
| 2016 FY | 162.37 Million USD | 42.47% |
| 2016 Q4 | 46.25 Million USD | 20.33% |
| 2015 Q2 | 25.32 Million USD | 14.8% |
| 2015 Q4 | 30.74 Million USD | -14.22% |
| 2015 Q1 | 22.05 Million USD | 7.76% |
| 2015 FY | 113.97 Million USD | 76.94% |
| 2015 Q3 | 35.84 Million USD | 41.55% |
| 2014 Q3 | 16.85 Million USD | 17.38% |
| 2014 FY | 64.41 Million USD | 22.46% |
| 2014 Q4 | 20.46 Million USD | 21.42% |
| 2014 Q2 | 14.36 Million USD | 12.86% |
| 2014 Q1 | 12.72 Million USD | 3.79% |
| 2013 FY | 52.59 Million USD | 1.75% |
| 2013 Q4 | 12.26 Million USD | -3.73% |
| 2013 Q3 | 12.73 Million USD | -8.36% |
| 2013 Q2 | 13.89 Million USD | 1.4% |
| 2013 Q1 | 13.7 Million USD | 2.54% |
| 2012 Q3 | 13.31 Million USD | 11.47% |
| 2012 Q4 | 13.36 Million USD | 0.35% |
| 2012 FY | 51.69 Million USD | 19.08% |
| 2012 Q2 | 11.94 Million USD | -8.5% |
| 2012 Q1 | 13.05 Million USD | 22.47% |
| 2011 Q3 | 11.28 Million USD | 2.69% |
| 2011 Q4 | 10.66 Million USD | -5.48% |
| 2011 FY | 43.4 Million USD | -8.08% |
| 2011 Q1 | 10.57 Million USD | -25.47% |
| 2011 Q2 | 10.98 Million USD | 3.9% |
| 2010 Q4 | 14.18 Million USD | 19.6% |
| 2010 Q3 | 11.86 Million USD | 14.07% |
| 2010 FY | 47.22 Million USD | -6.75% |
| 2010 Q2 | 10.39 Million USD | -3.49% |
| 2010 Q1 | 10.77 Million USD | 12.31% |
| 2009 Q1 | 15.04 Million USD | -52.16% |
| 2009 FY | 50.63 Million USD | -44.52% |
| 2009 Q3 | 10.36 Million USD | -33.69% |
| 2009 Q4 | 9.59 Million USD | -7.46% |
| 2009 Q2 | 15.63 Million USD | 3.94% |
| 2008 Q2 | 20.85 Million USD | -7.38% |
| 2008 Q4 | 31.44 Million USD | 90.97% |
| 2008 FY | 91.27 Million USD | -57.24% |
| 2008 Q1 | 22.51 Million USD | -82.57% |
| 2008 Q3 | 16.46 Million USD | -21.03% |
| 2007 FY | 213.46 Million USD | 39.93% |
| 2007 Q1 | 27.37 Million USD | 6.52% |
| 2007 Q4 | 129.12 Million USD | 339.71% |
| 2007 Q3 | 29.36 Million USD | 6.41% |
| 2007 Q2 | 27.59 Million USD | 0.8% |
| 2006 Q2 | 38.5 Million USD | -18.19% |
| 2006 Q4 | 25.7 Million USD | -37.72% |
| 2006 FY | 152.55 Million USD | 2.41% |
| 2006 Q3 | 41.27 Million USD | 7.17% |
| 2006 Q1 | 47.07 Million USD | 21.61% |
| 2005 FY | 148.96 Million USD | 8.33% |
| 2005 Q3 | 39.62 Million USD | 0.51% |
| 2005 Q1 | 31.21 Million USD | -21.32% |
| 2005 Q2 | 39.42 Million USD | 26.3% |
| 2005 Q4 | 38.7 Million USD | -2.32% |
| 2004 FY | 137.51 Million USD | -30.5% |
| 2004 Q1 | 31.67 Million USD | -28.84% |
| 2004 Q2 | 28.43 Million USD | -10.21% |
| 2004 Q3 | 37.73 Million USD | 32.68% |
| 2004 Q4 | 39.66 Million USD | 5.13% |
| 2003 Q2 | 57.45 Million USD | 8.27% |
| 2003 FY | 197.86 Million USD | 62.64% |
| 2003 Q3 | 42.83 Million USD | -25.45% |
| 2003 Q4 | 44.5 Million USD | 3.91% |
| 2003 Q1 | 53.06 Million USD | 17.53% |
| 2002 Q3 | 27.48 Million USD | 4.71% |
| 2002 FY | 121.66 Million USD | 42.92% |
| 2002 Q4 | 45.15 Million USD | 64.28% |
| 2002 Q2 | 26.24 Million USD | 15.23% |
| 2002 Q1 | 22.77 Million USD | -19.33% |
| 2001 Q2 | 18.92 Million USD | 7.7% |
| 2001 Q3 | 20.4 Million USD | 7.82% |
| 2001 FY | 85.12 Million USD | 62.49% |
| 2001 Q1 | 17.56 Million USD | 13.81% |
| 2001 Q4 | 28.23 Million USD | 38.42% |
| 2000 FY | 52.38 Million USD | 35.02% |
| 2000 Q2 | 10.85 Million USD | 3.18% |
| 2000 Q4 | 15.43 Million USD | -0.87% |
| 2000 Q3 | 15.57 Million USD | 43.41% |
| 2000 Q1 | 10.52 Million USD | 7.38% |
| 1999 Q1 | 8.7 Million USD | 58.18% |
| 1999 Q2 | 9.5 Million USD | 9.2% |
| 1999 Q3 | 10.7 Million USD | 12.63% |
| 1999 FY | 38.8 Million USD | 28.9% |
| 1999 Q4 | 9.8 Million USD | -8.41% |
| 1998 Q2 | 6.6 Million USD | -4.35% |
| 1998 Q1 | 6.9 Million USD | -12.66% |
| 1998 FY | 30.1 Million USD | 11.9% |
| 1998 Q4 | 5.5 Million USD | -50.0% |
| 1998 Q3 | 11 Million USD | 66.67% |
| 1997 Q1 | 5.9 Million USD | -6.35% |
| 1997 Q3 | 6.9 Million USD | 15.0% |
| 1997 Q4 | 7.9 Million USD | 14.49% |
| 1997 FY | 26.9 Million USD | 55.49% |
| 1997 Q2 | 6 Million USD | 1.69% |
| 1996 Q1 | 2.6 Million USD | 0.0% |
| 1996 FY | 17.3 Million USD | 0.0% |
| 1996 Q2 | 4.4 Million USD | 69.23% |
| 1996 Q3 | 4 Million USD | -9.09% |
| 1996 Q4 | 6.3 Million USD | 57.5% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -19244.781% |
| Alpha Teknova, Inc. | 45.85 Million USD | -3381.323% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -714.611% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -3459.326% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -902.776% |
| Cosmos Health Inc. | 26.18 Million USD | -5997.983% |
| Journey Medical Corporation | 54.59 Million USD | -2824.314% |
| Embecta Corp. | 528.4 Million USD | -202.139% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -487.171% |
| Dynavax Technologies Corporation | 219.14 Million USD | -628.513% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | -170.59% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -389.158% |
| PainReform Ltd. | 9.58 Million USD | -16557.972% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -12064.301% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -12064.301% |
| SCYNEXIS, Inc. | 51.84 Million USD | -2979.193% |
| Safety Shot Inc | 12.1 Million USD | -13083.653% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -51917.016% |
| Procaps Group, S.A. | 199.47 Million USD | -700.343% |
| Theratechnologies Inc. | 72.75 Million USD | -2094.321% |
| Harrow Health, Inc. | 89.97 Million USD | -1674.421% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -16801.334% |
| Biofrontera Inc. | 39.95 Million USD | -3895.345% |
| DURECT Corporation | 43.71 Million USD | -3552.065% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -201.79% |
| Cronos Group Inc. | 96.7 Million USD | -1550.829% |
| OptiNose, Inc. | 85.1 Million USD | -1775.984% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -587.779% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -3977.593% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 16798.044% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -408.223% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -16306.61% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -3609.292% |
| Radius Health, Inc. | 265.92 Million USD | -500.348% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -11433.815% |
| ProPhase Labs, Inc. | 37.85 Million USD | -4117.743% |
| Phibro Animal Health Corporation | 260.29 Million USD | -513.335% |
| Procaps Group S.A. | 187.24 Million USD | -752.626% |
| Alvotech | 285.43 Million USD | -459.316% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -16149.364% |
| Viatris Inc. | 5.96 Billion USD | 73.24% |
| Rockwell Medical, Inc. | 15.37 Million USD | -10284.415% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -2567.948% |
| SIGA Technologies, Inc. | 22.04 Million USD | -7142.655% |
| Tilray Brands, Inc. | 251.35 Million USD | -535.152% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -3155.638% |
| Shineco, Inc. | 17.94 Million USD | -8795.122% |
| PetIQ, Inc. | 192.72 Million USD | -728.382% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -39901.122% |
| Incannex Healthcare Limited | 30.05 Million USD | -5212.282% |
| Alimera Sciences, Inc. | 62.64 Million USD | -2448.65% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -209279.246% |
| Assertio Holdings, Inc. | 368.58 Million USD | -333.143% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -27025.66% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -8864.804% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -7441.688% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -7487.172% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -867.775% |
| Hempacco Co., Inc. | 7.59 Million USD | -20916.399% |
| Talphera, Inc. | 11.99 Million USD | -13210.822% |
| Alvotech | 285.43 Million USD | -459.316% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -1034.571% |
| Lantheus Holdings, Inc. | 344.9 Million USD | -362.886% |
| Currenc Group, Inc. | 24 Million USD | -6551.504% |
| Kamada Ltd. | 45.42 Million USD | -3414.507% |
| Indivior PLC | 911 Million USD | -75.247% |
| Evoke Pharma, Inc. | 12.4 Million USD | -12764.996% |
| Flora Growth Corp. | 10.57 Million USD | -14991.218% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -7487.172% |
| Evolus, Inc. | 189.75 Million USD | -741.33% |
| HUTCHMED (China) Limited | 436.23 Million USD | -265.976% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -935.787% |
| Akanda Corp. | 3.48 Million USD | -45730.238% |